insulin degludec · Tresiba

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
CN
  • Diabetes (once-daily basal insulin)
Product first approved 2017biospace.com
EU
  • Treatment of diabetes mellitus in adults
Product first approved 2013EMA
JP
  • Diabetes mellitus requiring insulin therapy
Product first approved 2012PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (68)
Type 1 Diabetes
NCT03952130 · Eli Lilly and Company
2019-05-29 – 2022-01-10 · Type 1 Diabetes Mellitus
What this study did
NCT03377699 · Novo Nordisk A/S
2017-11-22 – 2020-12-17 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT03214367 · Eli Lilly and Company
2017-07-17 – 2019-08-22 · Type 1 Diabetes Mellitus
What this study did
NCT02670915 · Novo Nordisk A/S
2016-05-04 – 2018-03-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02500706 · Novo Nordisk A/S
2016-05-04 – 2017-08-16 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02034513 · Novo Nordisk A/S
2014-01-05 – 2016-01-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01513473 · Novo Nordisk A/S
2012-01-16 – 2013-07-30 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01569841 · Novo Nordisk A/S
2012-04 – 2012-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01079234 · Novo Nordisk A/S
2010-03 – 2011-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01074268 · Novo Nordisk A/S
2010-02 – 2010-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00982228 · Novo Nordisk A/S
2009-09-01 – 2010-11-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06559722 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2024-08 – 2026-02 · Type 2 Diabetes
What this study did
NCT05802862 · Sunshine Lake Pharma Co., Ltd.
2023-07-06 – 2024-08-16 · Diabetes
What this study did
NCT05767255 · Hospital Universitario San Ignacio
2022-12-01 – 2023-08-30 · Diabetes Mellitus, Type 2 Treated With Insulin
What this study did
NCT03862716 · Population Health Research Institute
2019-04-23 – 2023-07-31 · Type 2 Diabetes Mellitus
What this study did
NCT04588259 · Novo Nordisk A/S
2020-10-09 – 2022-08-05 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT03952143 · Eli Lilly and Company
2019-05-27 – 2021-01-20 · Type 2 Diabetes Mellitus
What this study did
NCT03172494 · Novo Nordisk A/S
2017-05-26 – 2019-07-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03214380 · Eli Lilly and Company
2017-07-14 – 2019-03-13 · Type 2 Diabetes Mellitus
What this study did
NCT03268005 · Novo Nordisk A/S
2017-09-19 – 2019-01-29 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02501161 · Novo Nordisk A/S
2016-01-31 – 2018-10-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02607306 · Novo Nordisk A/S
2015-11-18 – 2017-12-22 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02762578 · Novo Nordisk A/S
2016-05-03 – 2017-06-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02420262 · Novo Nordisk A/S
2015-07-26 – 2016-10-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02298192 · Novo Nordisk A/S
2014-11-21 – 2015-12-23 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02030600 · Novo Nordisk A/S
2014-01-06 – 2015-12-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01952145 · Novo Nordisk A/S
2013-09-20 – 2014-11-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01849289 · Novo Nordisk A/S
2013-06-02 – 2014-05-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01676116 · Novo Nordisk A/S
2012-08-29 – 2014-03-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01664247 · Novo Nordisk A/S
2012-10-01 – 2013-12-31 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01513590 · Novo Nordisk A/S
2012-01-16 – 2012-11-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01392573 · Novo Nordisk A/S
2011-11-28 – 2012-10-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01388361 · Novo Nordisk A/S
2011-09 – 2012-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (1)
Type 2 Diabetes
NCT03387787 · Insel Gruppe AG, University Hospital Bern
2018-01-30 – 2020-01-30 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (8)
Type 1 Diabetes
NCT04585776 · Eli Lilly and Company
2020-10-30 – 2021-05-27 · Type 1 Diabetes
What this study did
NCT00841087 · Novo Nordisk A/S
2009-01 – 2009-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00612040 · Novo Nordisk A/S
2008-01 – 2008-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT00842361 · Novo Nordisk A/S
2009-01 – 2009-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00611884 · Novo Nordisk A/S
2008-01 – 2008-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00613951 · Novo Nordisk A/S
2008-01 – 2008-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00614055 · Novo Nordisk A/S
2008-01 – 2008-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03938740 · Diasome Pharmaceuticals
2019-03-18 – 2020-03-18 · Diabetes Mellitus, Type 1
What this study did
Phase 1 (52)
Type 1 Diabetes
NCT04569994 · Novo Nordisk A/S
2020-09-30 – 2021-06-23 · Healthy Volunteers, Diabetes Mellitus, Type 1
What this study did
NCT03400501 · Yale University
2017-10-01 – 2021-06-07 · Type 1 Diabetes Mellitus
What this study did
NCT02536859 · Novo Nordisk A/S
2015-08-31 – 2016-04-14 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01773798 · Novo Nordisk A/S
2013-01 – 2013-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01704417 · Novo Nordisk A/S
2012-10 – 2013-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01590836 · Novo Nordisk A/S
2012-04 – 2012-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01455142 · Novo Nordisk A/S
2011-10 – 2012-01 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01173926 · Novo Nordisk A/S
2010-07 – 2010-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01174303 · Novo Nordisk A/S
2010-08 – 2010-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01138488 · Novo Nordisk A/S
2010-06 – 2010-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01135927 · Novo Nordisk A/S
2010-06 – 2010-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01114542 · Novo Nordisk A/S
2010-05-03 – 2010-08-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01076634 · Novo Nordisk A/S
2010-02 – 2010-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01030926 · Novo Nordisk A/S
2009-12 – 2010-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01051102 · Novo Nordisk A/S
2010-01 – 2010-04 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00964418 · Novo Nordisk A/S
2009-08 – 2009-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00961324 · Novo Nordisk A/S
2009-07-27 – 2009-10-26 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01868568 · Novo Nordisk A/S
2008-04 – 2008-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01868529 · Novo Nordisk A/S
2008-01 – 2008-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01865318 · Novo Nordisk A/S
2006-09 – 2007-01 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06288412 · Novo Nordisk A/S
2024-02-26 – 2025-04-14 · Diabetes Mellitus, Type 2
What this study did
NCT03292185 · Novo Nordisk A/S
2017-09-29 – 2018-01-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01916174 · Novo Nordisk A/S
2013-08 – 2013-11 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01467414 · Novo Nordisk A/S
2011-10 – 2011-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01134224 · Novo Nordisk A/S
2010-05 – 2010-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01154881 · Novo Nordisk A/S
2010-06 – 2010-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01043510 · Novo Nordisk A/S
2010-01 – 2010-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01865292 · Novo Nordisk A/S
2006-08 – 2006-11 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT01865279 · Novo Nordisk A/S
2005-12 – 2006-04 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06449703 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2024-05-06 – 2024-06-16 · Healthy
What this study did
NCT06556641 · Gan and Lee Pharmaceuticals, USA
2022-12-17 – 2023-02-03 · Healthy Subjects
What this study did
NCT03726125 · Eli Lilly and Company
2018-11-20 – 2019-09-27 · Healthy
What this study did
NCT02844790 · Novo Nordisk A/S
2016-07-26 – 2016-09-27 · Healthy
What this study did
NCT01623375 · Novo Nordisk A/S
2012-06 – 2012-08 · Diabetes, Healthy
What this study did
NCT01437592 · Novo Nordisk A/S
2011-09-06 – 2011-11-22 · Diabetes, Healthy
What this study did
NCT01319240 · Novo Nordisk A/S
2011-03 – 2011-05 · Diabetes, Healthy
What this study did
NCT01193387 · Novo Nordisk A/S
2010-08 – 2010-11 · Diabetes, Healthy
What this study did
NCT01151072 · Novo Nordisk A/S
2010-06 – 2010-10 · Diabetes, Healthy
What this study did
NCT01125553 · Novo Nordisk A/S
2010-05 – 2010-08 · Diabetes, Healthy
What this study did
NCT01002768 · Novo Nordisk A/S
2009-10 – 2010-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00992537 · Novo Nordisk A/S
2009-10 – 2010-01 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00983021 · Novo Nordisk A/S
2009-09 – 2009-12 · Diabetes, Healthy
What this study did
NCT00993096 · Novo Nordisk A/S
2009-09 – 2009-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00966368 · Novo Nordisk A/S
2009-08 – 2009-10 · Diabetes, Healthy
What this study did
NCT01868581 · Novo Nordisk A/S
2008-05 – 2008-08 · Diabetes, Healthy
What this study did
Phase 4 (17)
Type 1 Diabetes
NCT05904743 · Mannkind Corporation
2023-07-07 – 2024-06-24 · Diabetes Mellitus, Type 1
What this study did
NCT05243628 · Mannkind Corporation
2022-03-31 – 2022-10-17 · Type 1 Diabetes
What this study did
NCT03328845 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2017-01-20 – 2021-11-20 · Type 1 Diabetes Mellitus
What this study did
NCT03987191 · University of Colorado, Denver
2020-01-10 – 2020-10-08 · Type 1 Diabetes
What this study did
NCT03668808 · Sansum Diabetes Research Institute
2018-11-16 – 2020-09-19 · Diabetes Mellitus, Type 1
What this study did
NCT03838783 · LMC Diabetes & Endocrinology Ltd.
2018-05-15 – 2019-06-30 · Type 1 Diabetes Mellitus
What this study did
NCT02192450 · Nordsjaellands Hospital
2015-01 – 2019-02-28 · Type 1 Diabetes Mellitus, Nocturnal Hypoglycemia, Recurrent Severe Hypoglycaemia
What this study did
Type 2 Diabetes
NCT07173712 · Yanbing Li
2026-03-15 – 2027-12-31 · Type 2 Diabetes
What this study did
NCT06408532 · Peking University People's Hospital
2024-04-30 – 2025-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT04538352 · The Cleveland Clinic
2021-01-18 – 2023-11-01 · Type 2 Diabetes
What this study did
NCT05360537 · University of Palermo
2021-04-01 – 2022-04-20 · Diabetes Mellitus, Type 2
What this study did
NCT03336528 · Emory University
2018-01-02 – 2021-03-01 · Type 2 Diabetes
What this study did
NCT03687827 · Novo Nordisk A/S
2018-10-02 – 2019-12-27 · Diabetes Mellitus, Type 2
What this study did
NCT04692415 · University of Split, School of Medicine
2018-12-15 – 2019-06-27 · Diabetes Mellitus, Type 2
What this study did
NCT03349840 · Weill Cornell Medical College in Qatar
2018-01-07 – 2018-12-31 · Type2 Diabetes
What this study did
NCT03244241 · Merete Bechmann Christensen
2017-04-01 – 2018-04-01 · Type 2 Diabetes Mellitus
What this study did
NCT02680457 · University of Guadalajara
2013-11 – 2016-11 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (6)
Type 1 Diabetes
NCT03497260 · Insel Gruppe AG, University Hospital Bern
2019-01-04 – 2019-09-08 · Type 1 Diabetes Mellitus, Diabetes Complications
What this study did
Type 2 Diabetes
NCT05417841 · Beijing Hospital
2023-03-23 – 2025-08-15 · Type 2 Diabetes Mellitus
What this study did
NCT04190160 · Stefano Rizza
2018-11-19 – 2021-03-25 · Type2 Diabetes
What this study did
NCT03091712 · Glooko
2017-05-05 – 2019-09-15 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06178874 · Ain Shams University
2023-12-01 – 2024-06-01 · Glycemic Control, Insulin, Critical Illness
What this study did
NCT03001323 · Hennepin Healthcare Research Institute
2017-01 – 2020-09-25 · Diabetes Mellitus
What this study did
Used as active comparator (34)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (13)
Type 1 Diabetes
NCT05463744 · Eli Lilly and Company
2022-08-12 – 2024-05-07 · Type 1 Diabetes, Diabetes
What this study did
NCT03740919 · Eli Lilly and Company
2019-04-07 – 2021-07-02 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT07913061 · Jiangsu HengRui Medicine Co., Ltd.
2026-11 – 2028-02 · Diabetes Mellitus, Type 2
What this study did
NCT07527078 · Gan & Lee Pharmaceuticals.
2026-04-07 – 2027-04-17 · Type 2 Diabetes (T2DM)
What this study did
NCT06767748 · Gan & Lee Pharmaceuticals.
2025-02-15 – 2026-02-28 · Diabetes
What this study did
NCT04955834 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021-07-27 – 2025-12-31 · Type 2 Diabetes
What this study did
NCT05275400 · Eli Lilly and Company
2022-03-08 – 2024-05-15 · Type 2 Diabetes
What this study did
NCT05362058 · Eli Lilly and Company
2022-06-03 – 2024-04-10 · Diabetes, Type 2 Diabetes
What this study did
NCT03882970 · Eli Lilly and Company
2019-04-01 – 2021-01-04 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT03737240 · Emory University
2019-01-15 – 2022-07-08 · Diabetes Mellitus
What this study did
Phase 2 (7)
Type 1 Diabetes
NCT04450407 · Eli Lilly and Company
2020-07-06 – 2021-10-01 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT07387003 · Gan & Lee Pharmaceuticals.
2026-04-10 – 2027-09-23 · Type 2 Diabetes (T2DM)
What this study did
NCT07018453 · Jiangsu HengRui Medicine Co., Ltd.
2025-07-16 – 2026-05 · Type 2 Diabetes Mellitus
What this study did
NCT06202079 · Gan and Lee Pharmaceuticals, USA
2023-08-11 – 2024-08-08 · Diabetes Mellitus, Type 2
What this study did
NCT04663282 · Jiangsu HengRui Medicine Co., Ltd.
2021-02-04 – 2022-05-28 · Type 2 Diabetes
What this study did
NCT04450394 · Eli Lilly and Company
2020-07-01 – 2021-10-08 · Type 2 Diabetes Mellitus
What this study did
NCT03736785 · Eli Lilly and Company
2018-11-15 – 2020-02-18 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (8)
Type 1 Diabetes
NCT06280703 · Eli Lilly and Company
2024-05-15 – 2026-10-03 · Healthy, Type 1 Diabetes Mellitus
What this study did
NCT06685185 · Novo Nordisk A/S
2024-11-12 – 2026-03-18 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT07630233 · The United Bio-Technology (Hengqin) Co., Ltd.
2026-06-17 – 2026-10-25 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06132126 · Eli Lilly and Company
2023-11-17 – 2024-06-28 · Healthy, Type 2 Diabetes Mellitus
What this study did
NCT06553248 · Gan and Lee Pharmaceuticals, USA
2023-03-22 – 2023-11-01 · Diabetes
What this study did
NCT04276428 · Eli Lilly and Company
2020-02-28 – 2020-11-28 · Diabetes Mellitus, Type 2
What this study did
NCT02148861 · Novo Nordisk A/S
2014-05-26 – 2015-06-01 · Diabetes, Type 2 Diabetes Mellitus
What this study did
Phase 4 (5)
Type 1 Diabetes
NCT04075513 · Sanofi
2019-10-09 – 2021-09-16 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT05552859 · Sanofi
2022-12-05 – 2023-08-04 · Type 2 Diabetes Mellitus, Renal Impairment
What this study did
Early phase / not applicable (1)
Type 1 Diabetes
NCT04965051 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-08 – 2023-12 · Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Type 1 Diabetes
NCT00978627 · Novo Nordisk A/S
2009-08 – 2010-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 1 (1)
Type 2 Diabetes
NCT07032688 · Jiangsu HengRui Medicine Co., Ltd.
2025-08-11 – 2027-04 · Type 2 Diabetes
What this study did
Phase 4 (2)
Type 1 Diabetes
NCT04623086 · University of Washington
2020-02-14 – 2023-12-31 · Type 1 Diabetes
What this study did
Other / comorbidity
NCT05218915 · Elaine Chow
2022-01-28 – 2024-10-30 · Diabetes Mellitus, Diabetic Kidney Disease
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Degludec (Tresiba): this drugApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tresiba (insulin degludec) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-06-30 · NCT07173712 · CT.gov ↗
What to watch

See the full readout calendar ↗